Status:

COMPLETED

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Gastrointestinal Stromal Tumors

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This study is an open-label, multicenter, Phase I dose-escalation study of the combination of AMN107 and imatinib (STI571) in patients with imatinib-resistant GIST. This study is designed to determine...

Eligibility Criteria

Inclusion

  • Patients with gastrointestinal stromal tumor (GIST).
  • Patients who have had disease progression during imatinib therapy with 800 mg.
  • Ability to understand and willingness to sign a written informed consent document.

Exclusion

  • Patients with prior or concomitant malignancies other than GIST with the exception of previous or concomitant basal cell skin cancer or previous cervical carcinoma in situ.
  • A history of impaired cardiac function or uncontrolled cardiovascular disease.
  • Severe and/or uncontrolled concurrent disease that could cause unacceptable safety risks such as impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AMN107.
  • Currently taking certain medications that could affect an electrocardiogram result.
  • Women who are pregnant or breast feeding.
  • Patients unwilling or unable to comply with the protocol.
  • NOTE: Additional inclusion and/ or exclusion criteria may apply.

Key Trial Info

Start Date :

August 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2006

Estimated Enrollment :

59 Patients enrolled

Trial Details

Trial ID

NCT00135005

Start Date

August 1 2005

End Date

November 1 2006

Last Update

December 8 2020

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Novartis Investigative Site

Boston, Massachusetts, United States, 02115

2

Novartis Investigative Site

Philadelphia, Pennsylvania, United States, 19111-2497

3

Novartis Investigative Site

Lyon, France, 69373

4

Novartis Investigative Site

Berlin, Germany, 13125